Lymphocyte to Procalcitonin Ratio in Covid-19 Patients

NCT06620159 · tracked via the Priya Life Science Turkey tracker

Sponsor

Suleyman Demirel University

Phase

Observational

Started

2020-04-01

Last updated

2024-10-03

Condition(s) studied

COVID-19

Study summary

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

Eligibility

Sex

ALL

Min age

23 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * Covid19 PCR test positive Exclusion Criteria: * Pregnancy Under 18 years old

Primary outcome measure(s)

outcome — 30 days
The relationship between lymphocyte/procalcitonin ratio and 30-day mortality was analyzed.

Trial sites (1)

Facility	City	Region	Status
Süleyman demirel üniversitesi tıp fakültesi	Isparta	Turkey (Türkiye)

More Suleyman Demirel University trials in Turkey

Effectiveness of a Visual Feedback Exercise Program Following Lumbar Surgery Recruiting

Effectiveness of Standard Exercises and Wall Angels Exercise in Young Adults With Kyphotic Posture Enrolling by invitation

Impact of Podcast-Based Breastfeeding Education During Pregnancy on Breastfeeding Self-Efficacy in Pregnant Women Enrolling by invitation

Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention Active, not recruiting

"Evaluation of the Epidemiology of Surgically Treated Acute Traumatic Peripheral Nerve Injuries of the Upper Extremity and Their Long-Term Effects on Sensory and Motor, Functional Status, and Quality of Life" Recruiting

Other trials for the same condition

TDCS Stimulation After Covid-19 Infection Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06620159 on ClinicalTrials.gov ↗ ← All trials in Turkey